Amgen's most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $167.50 short call and a strike $172.50 long call offers a potential 15.47% return on risk over the next 18 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $167.50 by expiration. The full premium credit of $0.67 would be kept by the premium seller. The risk of $4.33 would be incurred if the stock rose above the $172.50 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Amgen
Healthcare Winners and Losers Following the AHCA's Failure
Sun, 02 Apr 2017 19:02:00 GMT
Better Buy: Celgene Corporation vs. Amgen Inc.
Sat, 01 Apr 2017 15:42:00 GMT
Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)
Sat, 01 Apr 2017 15:30:00 GMT
PR Newswire – In the study, postmenopausal women with low bone mass (lumbar spine, total hip or femoral neck T score between -2.0 and -3.5) were initially randomized to various doses of EVENITY or placebo for 24 months and then re-randomized to receive denosumab (Prolia®) or placebo for the next 12 months (24 to 36 months), as previously reported. For months 36 to 48, all of these patients were then treated with EVENITY (210 mg) for 12 months.
FDA Grants Amgen Priority Review for Blincyto sBLA
Fri, 31 Mar 2017 19:36:30 GMT
Also on Market Tamer…
Follow Us on Facebook